drugset

drugset / Trial / NCT00380276

Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol

NCT00380276 ↗

Phase 3 Terminated 1000 enrolled Myrexis Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Open-label treatment with MPC-7869 for participants in a previous randomized study.

Timeline

Start: 2006-09
Primary completion: —
Completion: 2008-12

Outcome

Outcome not reported

Stopped: “Myriad has discontinued the development of Flurizan.”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	tarenflurbil	Small molecule	800 mg	Oral

Indications